Valbiotis Successfully Executes €10.2M Capital Increase

Valbiotis, a French laboratory focused on developing scientifically tested natural products, has successfully increased its capital by €10.2 million. This financial boost aims to accelerate Valbiotis' commercial expansion both in France and internationally, supporting its goal of addressing cardiometabolic imbalances.

The company maintained preferential subscription rights, receiving a total demand of approximately €6.2 million. Valbiotis' robust growth strategy is supported by shareholders, institutional investors, and its Chinese partner, Xianhua Tao, through Ximen RD PTE Ltd. These funds are allocated to customer and inventory working capital (62%), sales force expansion (25%), and marketing efforts (13%).

Settlement and trading of new shares on Euronext Growth Paris are expected by June 30, 2026, increasing Valbiotis’ share capital to €3,553,823.40. The capital increase will extend Valbiotis' cash runway beyond Q3 2027, aiming for positive EBITDA by fiscal year 2027.